Product Description
Levofloxacin is used to treat bacterial infections in many different parts of the body. It is also used to treat anthrax infection after inhalational exposure. Levofloxacin is also used to treat and prevent plague (including pneumonic and septicemic plague). (Sourced from: https://www.mayoclinic.org/drugs-supplements/levofloxacin-oral-route/description/drg-20064518)
Mechanisms of Action: TOP2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Intravenous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Anthrax | Plague | Pneumonia, Bacterial | Urinary Tract Infections | Prostatitis | Nephritis | Pyelonephritis | Bronchitis | Bronchitis, Chronic | Pneumonia | Sinusitis | Anthrax | Plague | Pneumonia, Bacterial | Urinary Tract Infections | Prostatitis | Nephritis | Pyelonephritis | Bronchitis | Bronchitis, Chronic | Pneumonia | Sinusitis
Known Adverse Events: Aneurysm | Dizziness | Headache | Insomnia | Colitis | Hepatitis | Hepatitis, Chronic | Thrombocytopenia | Myasthenia Gravis | Drug Hypersensitivity | Hypersensitivity, Immediate | Nut Hypersensitivity | Anthrax | Central Nervous System Bacterial Infections | Clostridium Infections | Plague | Pneumonia, Bacterial | Urinary Tract Infections | Muscle Weakness | Hypokalemia | Prostatitis | Nephritis | Pyelonephritis | Bronchitis | Bronchitis, Chronic | Pneumonia | Sinusitis | Asthenia | Constipation | Diarrhea | Agranulocytosis
Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, Germany, Italy, Japan, Philippines, Russia, Spain, Vietnam
Active Clinical Trial Count: 6
Highest Development Phases
Phase 3: Myelodysplastic Syndrome|Pneumonia, Mycoplasma
Phase 2: Conjunctivitis, Bacterial|Tuberculosis, Multidrug-Resistant
Phase 1: Abscess|Appendicitis|Bacteroides Infections|Clostridium Infections|Endometritis|Fusobacterium Infections|Pelvic Infection|Pelvic Inflammatory Disease|Peritonitis|Salpingitis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| DRAMATIC | P2 |
Recruiting |
Tuberculosis, Multidrug-Resistant |
2027-05-01 |
|
| MIRAKLE | P2 |
Completed |
Conjunctivitis, Bacterial |
2023-06-14 |
|
| CTR20222765 | P1 |
Completed |
Bacteroides Infections|Pelvic Inflammatory Disease|Abscess|Clostridium Infections|Endometritis|Peritonitis|Fusobacterium Infections|Appendicitis|Pelvic Infection|Salpingitis |
2022-12-18 |
|
| MIRAKLE | P2 |
Active, not recruiting |
Conjunctivitis, Bacterial |
2022-03-26 |